The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France.

CompletedOBSERVATIONAL
Enrollment

306

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

May 19, 2022

Study Completion Date

October 27, 2022

Conditions
Type 1 Diabetes
Interventions
DEVICE

MiniMed™ 780G System

Subject enrolled in the study will start using the MiniMed™ 780G pump in Auto Mode after a run-in period of two weeks in Manual Mode (with no SmartGuard™ functions). Study phase in Automode will follow a 6 and 12 months follow- up as per standard of care.

Trial Locations (32)

Unknown

CHU Angers, Angers

CHU Besançon, Besançon

APHP Avicenne, Bobigny

CHU Bordeaux (Saint-André), Bordeaux

CH Boulogne-Sur-Mer, Boulogne-sur-Mer

CHU Brest, Brest

HCL Groupement Hospitalier Est, Bron

CHU Caen, Caen

Ch Sud Francilien, Corbeil-Essonnes

CHU Dijon, Dijon

CHRU La Rochelle, La Rochelle

CHU Grenoble, La Tronche

CHU Lille, Lille

CHU Limoges, Limoges

HCL DIAB-eCARE, Lyon

IDNC Chartres, Mainvilliers

APHM Marseille (Hôpital de la Conception), Marseille

APHM Marseille (La Timone), Marseille

GHEF (Centre Hospitalier de Meaux), Meaux

CHU Montpellier (Lapeyronie), Montpellier

CHU Nantes, Nantes

CHU Nice, Nice

CHU Nîmes, Nîmes

APHP Bichat, Paris

APHP Cochin, Paris

Ch Lariboisiere, Paris

CH Perpignan, Perpignan

CH Périgueux, Périgueux

CHU Rennes, Rennes

CHU Strasbourg, Strasbourg

CHU Toulouse (Rangueil), Toulouse

CHU Tours, Tours

All Listed Sponsors
lead

Medtronic Diabetes

INDUSTRY

NCT04308291 - The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France. | Biotech Hunter | Biotech Hunter